ArticleFrontiers in pharmacology2020

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma.

Peiyao Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.